BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 33936075)

  • 1. Bispecific NKG2D-CD3 and NKG2D-CD16 Fusion Proteins as Novel Treatment Option in Advanced Soft Tissue Sarcomas.
    Hagelstein I; Lutz MS; Schmidt M; Heitmann JS; Malenke E; Zhou Y; Clar KL; Kopp HG; Jung G; Salih HR; Märklin M; Hinterleitner C
    Front Immunol; 2021; 12():653081. PubMed ID: 33936075
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bispecific NKG2D-CD3 and NKG2D-CD16 fusion proteins for induction of NK and T cell reactivity against acute myeloid leukemia.
    Märklin M; Hagelstein I; Koerner SP; Rothfelder K; Pfluegler MS; Schumacher A; Grosse-Hovest L; Jung G; Salih HR
    J Immunother Cancer; 2019 May; 7(1):143. PubMed ID: 31142382
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Boosting Natural Killer Cell-Mediated Targeting of Sarcoma Through DNAM-1 and NKG2D.
    Sayitoglu EC; Georgoudaki AM; Chrobok M; Ozkazanc D; Josey BJ; Arif M; Kusser K; Hartman M; Chinn TM; Potens R; Pamukcu C; Krueger R; Zhang C; Mardinoglu A; Alici E; Temple HT; Sutlu T; Duru AD
    Front Immunol; 2020; 11():40. PubMed ID: 32082316
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fc-optimized NKG2D-Fc constructs induce NK cell antibody-dependent cellular cytotoxicity against breast cancer cells independently of HER2/neu expression status.
    Raab S; Steinbacher J; Schmiedel BJ; Kousis PC; Steinle A; Jung G; Grosse-Hovest L; Salih HR
    J Immunol; 2014 Oct; 193(8):4261-72. PubMed ID: 25217158
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bispecific antibody-mediated redirection of NKG2D-CAR natural killer cells facilitates dual targeting and enhances antitumor activity.
    Zhang C; Röder J; Scherer A; Bodden M; Pfeifer Serrahima J; Bhatti A; Waldmann A; Müller N; Oberoi P; Wels WS
    J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34599028
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NKG2D functions as an activating receptor on natural killer cells in the common marmoset (Callithrix jacchus).
    Watanabe M; Kudo Y; Kawano M; Nakayama M; Nakamura K; Kameda M; Ebara M; Sato T; Nakamura M; Omine K; Kametani Y; Suzuki R; Ogasawara K
    Int Immunol; 2014 Nov; 26(11):597-606. PubMed ID: 24860119
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cancer immunotherapy using a bispecific NK receptor fusion protein that engages both T cells and tumor cells.
    Zhang T; Sentman CL
    Cancer Res; 2011 Mar; 71(6):2066-76. PubMed ID: 21282338
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fusion Proteins of NKG2D/NKG2DL in Cancer Immunotherapy.
    Ding H; Yang X; Wei Y
    Int J Mol Sci; 2018 Jan; 19(1):. PubMed ID: 29316666
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Distribution of several activating and inhibitory receptors on CD3-CD16+ NK cells and their correlation with NK cell function in healthy individuals.
    Konjević G; Mirjacić Martinović K; Vuletić A; Jurisić V; Spuzić I
    J Membr Biol; 2009 Aug; 230(3):113-23. PubMed ID: 19711124
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An Fc-optimized NKG2D-immunoglobulin G fusion protein for induction of natural killer cell reactivity against leukemia.
    Steinbacher J; Baltz-Ghahremanpour K; Schmiedel BJ; Steinle A; Jung G; Kübler A; André MC; Grosse-Hovest L; Salih HR
    Int J Cancer; 2015 Mar; 136(5):1073-84. PubMed ID: 25046567
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incorporation of a Novel CD16-Specific Single-Domain Antibody into Multispecific Natural Killer Cell Engagers With Potent ADCC.
    van Faassen H; Jo DH; Ryan S; Lowden MJ; Raphael S; MacKenzie CR; Lee SH; Hussack G; Henry KA
    Mol Pharm; 2021 Jun; 18(6):2375-2384. PubMed ID: 33999642
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expansion of cytotoxic natural killer cells using irradiated autologous peripheral blood mononuclear cells and anti-CD16 antibody.
    Lee HR; Son CH; Koh EK; Bae JH; Kang CD; Yang K; Park YS
    Sci Rep; 2017 Sep; 7(1):11075. PubMed ID: 28894091
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Natural ligands and antibody-based fusion proteins: harnessing the immune system against cancer.
    Vyas M; Koehl U; Hallek M; von Strandmann EP
    Trends Mol Med; 2014 Feb; 20(2):72-82. PubMed ID: 24268686
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Shedding of CD16 disassembles the NK cell immune synapse and boosts serial engagement of target cells.
    Srpan K; Ambrose A; Karampatzakis A; Saeed M; Cartwright ANR; Guldevall K; De Matos GDSC; Önfelt B; Davis DM
    J Cell Biol; 2018 Sep; 217(9):3267-3283. PubMed ID: 29967280
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Factor VIII moiety of recombinant Factor VIII Fc fusion protein impacts Fc effector function and CD16
    Lagassé HAD; Ou J; Sauna ZE; Golding B
    Front Immunol; 2024; 15():1341013. PubMed ID: 38655263
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chimeric NKG2D CAR-expressing T cell-mediated attack of human ovarian cancer is enhanced by histone deacetylase inhibition.
    Song DG; Ye Q; Santoro S; Fang C; Best A; Powell DJ
    Hum Gene Ther; 2013 Mar; 24(3):295-305. PubMed ID: 23297870
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel NKG2D-directed bispecific antibodies enhance antibody-mediated killing of malignant B cells by NK cells and T cells.
    Lutz S; Klausz K; Albici AM; Ebinger L; Sellmer L; Teipel H; Frenzel A; Langner A; Winterberg D; Krohn S; Hust M; Schirrmann T; Dübel S; Scherließ R; Humpe A; Gramatzki M; Kellner C; Peipp M
    Front Immunol; 2023; 14():1227572. PubMed ID: 37965326
    [TBL] [Abstract][Full Text] [Related]  

  • 18. T and NK cells of B cell NHL patients exert cytotoxicity against lymphoma cells following binding of bispecific tetravalent antibody CD19 × CD3 or CD19 × CD16.
    Pörtner LM; Schönberg K; Hejazi M; Brünnert D; Neumann F; Galonska L; Reusch U; Little M; Haas R; Uhrberg M
    Cancer Immunol Immunother; 2012 Oct; 61(10):1869-75. PubMed ID: 22976535
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The bispecific B7H3xCD3 antibody CC-3 induces T cell immunity against bone and soft tissue sarcomas.
    Holzmayer SJ; Liebel K; Hagelstein I; Salih HR; Märklin M
    Front Immunol; 2024; 15():1391954. PubMed ID: 38765008
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Functional Domain Order of an Anti-EGFR × Anti-CD16 Bispecific Diabody Involving NK Cell Activation.
    Kuwahara A; Nagai K; Nakanishi T; Kumagai I; Asano R
    Int J Mol Sci; 2020 Nov; 21(23):. PubMed ID: 33255436
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.